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ABSTRACT
Approximately one-quarter of circulating cobalamin (vitamin B-12)
binds to transcobalamin (holoTC) and is thereby available for the
cells of the body. For this reason, holoTC is also referred to as active
vitamin B-12. HoloTC was suggested as an optimal marker of early
vitamin B-12 deﬁciency .20 y ago. This suggestion led to the de-
velopment of suitable assays for measurement of the compound and
clinical studies that aimed to show the beneﬁt of measurement of
holoTC rather than of vitamin B-12. Today holoTC can be analyzed
by 3 methods: direct measurement of the complex between trans-
cobalamin and vitamin B-12, measurement of vitamin B-12 attached
to transcobalamin, or measurement of the amount of transcobalamin
saturated with vitamin B-12. These 3 methods give similar results,
but direct measurement of holoTC complex is preferable in the clin-
ical setting from a practical point of view. HoloTC measurement has
proven useful for the identiﬁcation of the few patients who suffer
from transcobalamin deﬁciency. In addition, holoTC is part of the
CobaSorb test and therefore useful for assessment of vitamin B-12
absorption. Clinical studies that compare the ability of holoTC and
vitamin B-12 to identify individuals with vitamin B-12 deﬁciency
(elevated concentration of methylmalonic acid) suggest that holoTC
performs better than total vitamin B-12. To date, holoTC has not been
used for population-based assessments of vitamin B-12 status, but we
suggest that holoTC is a better marker than total vitamin B-12 for
such studies. Am J Clin Nutr doi: 10.3945/ajcn.111.013458.
INTRODUCTION
Why does one measure cobalamin (vitamin B-12) rather
than the fraction of the vitamin that can enter the cells, holo-
transcobalamin (holoTC)? In the 1980s the late Victor Herbert
frequentlyaskedthisquestion(1).Atthetime,holoTCcouldonly
be measured by calculation of the difference between vitamin
B-12 (eg, 500 pmol/L) and the fraction of vitamin B-12 that was
not attached to transcobalamin (eg, 420 pmol/L). As a result, the
uncertainty of the holoTC values was too large to allow proper
evaluation of holoTC’s clinical usefulness compared with other
markers of vitamin B-12 status [plasma cobalamin (vitamin B-
12), homocysteine (tHcy), and methylmalonic acid (MMA)].
Today several suitable methods are available to measure holoTC,
and data on its analytic and clinical aspects are accumulating
rapidly.
The present review summarizes current knowledge about the
analytic aspects and concerning determinants of plasma holoTC.
This review also addresses the clinical performance of holoTC
compared with that of total vitamin B-12. We conclude that mea-
surement of holoTC is also likely to be valuable for population-
wide screening of vitamin B-12 status.
HoloTC AND OTHER MARKERS OF VITAMIN B-12
STATUS
Plasma vitamin B-12 is bound to 2 proteins, transcobalamin
and haptocorrin (Figure 1). Transcobalamin carries a minor part
of the circulating vitamin B-12, and only ’10% of the protein is
saturated with vitamin B-12 (2). Transcobalamin transports vi-
tamin B-12 into all cells of the body and is responsible for the
transport of ’4 nmol of vitamin B-12 every day (3).
Haptocorrin is an almost fully saturated vitamin B-12 binding
glycoprotein of unknown function that carries the major part of
circulatingvitaminB-12and,inaddition,theinactiveformsofthe
vitamin, the so-called analogs. The metabolism of the protein is
slow,withaturnoverof’0.1nmolvitaminB-12everyday(4–6).
We and others have established methods for research purposes
that are suitable for measurement of transcobalamin and hapto-
corrin, whether saturated or not (7–9). However, clinicians have
beeninterestedmainlyinmeasurementsoftotalvitaminB-12(10)
and holoTC.
The fact that only vitamin B-12 that binds to transcobalamin is
available for cells has fostered the concept that measurement of
holoTCwouldbemoreclinicallymeaningfulthanmeasurementof
total vitamin B-12 (all of the vitamin B-12 that binds to trans-
cobalamin and haptocorrin). Several years ago, Victor Herbert
suggested staging vitamin B-12 status with holoTC as the ﬁrst
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Whereas plasma vitamin B-12 and holoTC concentrations can
be used as a measure of the amount of vitamin B-12 available for
the body’s cells, the metabolites tHcy and MMA mirror any lack
of vitamin B-12 within the cells. Both plasma tHcy and MMA
accumulate in vitamin B-12–deﬁcient patients (Figure 2). In
general, tHcy has low speciﬁcity because it also increases in
patients with folate and possibly thiamine and vitamin B-6 de-
ﬁciency (14). However, in a folate-fortiﬁed population, tHcy’s
speciﬁcity as a marker of vitamin B-12 deﬁciency is consider-
ably better (15). MMA is a sensitive marker of vitamin B-12
deﬁciency, and an elevated MMA concentration is often used as
a gold standard for classiﬁcation of a patient’s status as vitamin
B-12 deﬁcient or nondeﬁcient. Major drawbacks are the low
speciﬁcity of marginally elevated MMAvalues and the test’s limited
availability (16).
In otherwise healthy individuals, all 4 tests (vitamin B-12,
holoTC, tHcy, and MMA) have a strong relation to vitamin B-12
intake,withsteadystateconcentrationsatadailyintakeof4–7lg
vitamin B-12 (17). Indirectly, such studies suggest that all 4
markers may be useful for monitoring a population’s vitamin
B-12 status over time.
HoloTC MEASUREMENT
Three different types of holoTC measurement methods are avail-
ableand, as described below, we have shown that these methods
givereasonablysimilarvalues.Theﬁrstapproachtobepublished
combined ionic precipitation of transcobalamin with measure-
ment of the amount of vitamin B-12 trapped in the precipitate
(18–20).Lindemansetal(21)improvedthisapproachwiththeuseof
antibodiesdirectedtotranscobalaminratherthanionicseparation,
and Ulleland et al (22) developed a version of this approach that
involved measurement of trapped vitamin B-12 by an isotope
dilution assay, the holoTC-radioimmunoassay (RIA). In another
version, Refsum et al (9) measured vitamin B-12 with the use of
amicrobiologicalmethod.Yetanotherapproachistoremoveapo-
transcobalamin with vitamin B-12–coated beads followed by
enzyme-linkedimmunosorbentassaymeasurementoftheholoTC
that remains in the supernatant ﬂuid (23).
A multicenter study that involved 4 European laboratories
evaluatedtheholoTC-RIA(calibrationcurve:10–160pmol/L)and
theholoTC–enzyme-linkedimmunosorbentassay(calibrationcurve:
1.6–100 pmol/L) (24). The results from the study showed similar
values across laboratories and across the methods tested. The long-
term imprecision was 6% for the enzyme-linked immunosorbent
assay and .10% for the RIA (24). The RIA assay results were
also similar to the results that Refsum et al (9) obtained with the use
of the microbiological assay (calibration curve: 1.36–24.5 pmol/L;
imprecision: 4–7%).
Today,theholoTC-RIAhasbeenreplacedbyanassaythatuses
holoTC-speciﬁc monoclonal antibodies (25). On the AxSYM
platform (Abbott Labs, North Chicago, IL), the method has
a measurement range of 3–100 pmol/L and a total imprecision of
6–9%. The results obtained by this method compare well with
those of the holoTC-RIA (26, 27).
HoloTC DETERMINANTS
When a marker is used to monitor a population’s vitamin B-12
status, it should be remembered that an elevation in holoTC or
vitamin B-12 concentration or a decrease in MMA or tHcy con-
centration by determinants other than vitamin B-12 deﬁciency
predictsaspurioussufﬁcientstatus.Obviously,theoppositeistrue
for prediction of a spurious insufﬁcient status.
We and others have documented holoTC determinants not re-
latedtovitaminB-12status.Theresultsaresummarizedbelowand,
to some extent, in relation to determinants for other markers of
vitamin B-12 status.
Blood sampling and storage
HoloTC, like vitamin B-12, is a stable analyte and no special
precautions need to be taken to draw blood samples for holoTC
FIGURE 2. Markers of cobalamin [vitamin B-12 (B12)] status. The ﬁgure
shows the relation between vitamin B-12 deﬁciency markers. Holotransco-
balamin (holoTC) transports vitamin B-12 into the cells by binding to a spe-
ciﬁc receptor, CD320. In the cell, vitamin B-12 acts as a coenzyme for 2
enzymes. Methionine synthetase (5-methyltetrahydropteroyl-L-glutamate:
L-homocysteine-S-methyltransferase; EC 2.1.1.13), present in the cytoplasm,
converts homocysteine (tHcy) to methionine. Methylmalonyl–coenzyme A
(-CoA) mutases (methylmalonyl-CoA CoA-carbonylmutase; EC 5.4.99.2),
which are present in the mitochondria, are involved in the conversion of
methylmalonyl-CoA to succinyl-CoA. A decrease in holoTC results in a de-
crease in the cellular uptake of vitamin B-12. Once the cells become deﬁcient,
methylmalonic acid (MMA) and tHcy accumulate in the bloodstream; total
vitamin B-12 concentration decreases.
FIGURE 1. Cobalamin [vitamin B-12 (B12)] and its binding proteins in
human plasma. The ﬁgure shows the relation between the total concentration
of the vitamin B-12 binding proteins in plasma and the distribution of vitamin
B-12 and its analogs on the proteins. The average concentrations used are
as follows—total transcobalamin: 1000 pmol/L [holotranscobalamin
(HoloTC): 100 pmol/L; apotranscobalamin (ApoTC): 900 pmol/L]; total
haptocorrin: 450 pmol/L [vitamin B-12 bound to haptocorrin (B12HC): 200
pmol/L; vitamin B-12 analogs bound to haptocorrin (AnaHC): 200 pmol/L;
apohaptocorrin (ApoHC): 50 pmol/L]; total vitamin B-12: 300 pmol/L.
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probably for years. Loikas et al (28) examined stability systema-
tically for storage at –70C for up to 16 mo.
Diurnal variation
AmajorconcernhasbeenthepossibleelevationinholoTCafter
intake of vitamin B-12–rich food. The few studies that have ad-
dressed this issue have shown very limited variations related to
intake of a normal diet (9, 29) and because of that, blood can be
drawn both from fasting and nonfasting individuals. However,
repeatedintakesofhighphysiologicdosesofvitaminB-12(eg,9lg
3 times in 1 d) elevate the holoTC concentration (and to a lesser
degree the total vitamin B-12 concentration) within 24h (30). We
have used this ﬁnding to develop a clinical test for vitamin B-12
absorption, as described below.
Plasma compared with serum
EDTA plasma has shown slightly higher values for holoTC or
totaltranscobalamininsomestudies(22,31)butnotinothers(9).In
general, it is acceptable to use both plasma and serum to analyze
holoTC concentrations.
Sex, race, and life cycle
HoloTC,liketotalvitaminB-12,variestoalimitedextentbysex
orage.Note,however,thatRefsumetal(9)reportedslightlylower
concentrations in younger women. In contrast, we and others have
observed marked alterations in the metabolic markers, especially
tHcy, in relation to age and sex (32, 14).
Becausehaptocorrindecreases,totalvitaminB-12alsodecreases
in pregnant women, to ’50% at term compared with 2 mo post-
partum. In contrast, holoTC concentrations remain unchanged
during pregnancy (33, 34). For this reason, holoTC is better than
vitamin B-12 for monitoring of vitamin B-12 status in population-
based studies that include pregnant women. Information on racial
differencesinholoTCconcentrationsandothervitaminB-12status
markers is limited.
Total transcobalamin and holoTC
HoloTCaccountsfor5–20%oftotaltranscobalamin(23).Total
transcobalamin does not change in patients with vitamin B-12
deﬁciency (E Nexo, unpublished data, 2011). For this reason, we
have gained no additional information from the measurement of
transcobalamin saturation as opposed to holoTC measurement
alone (32). However, we observed a decrease in total trans-
cobalamin after healthy individuals were given a daily vitamin
B-12 dose of 500 lg. The concentration increased toward pre-
loading values within the following 84 d (35). This observation
mightrelatetothefactthatthecellularreceptorfortranscobalamin,
CD320,recognizesholoTCratherthanapotranscobalamin(36–38).
After vitamin B-12 provision, the cells absorb an elevated amount
ofholoTC.However,oncethecellsaresaturatedwithvitaminB-12,
total transcobalamin reaches a new equilibrium.
Transcobalamin genotypes
Transcobalamin occurs in many genotypes (39), and several
authors have clearly documented that the genotype present,
notably the P259R (TCN2 776C/G), inﬂuences the protein’s
total concentration. Total transcobalamin concentrations are
’20% lower in individuals with the 776GG genotype than in
individuals with the 776CC genotype; individuals with the 776GC
genotype have intermediate values. Genotype distribution varies
somewhat between studies but is ’30% for P259P (776CC),
50% for P259R (776CG), and 20% for R259R (776GG) (9).
HoloTC concentrations are inﬂuenced to a much lesser degree
by the transcobalamin genotypes, although this inﬂuence was
signiﬁcant in some studies (9, 40, 41).
Other diseases
Transcobalamin is a relatively small protein with a molecular
mass of ’40 kDa (42), and it is ﬁltered in the kidney. As a re-
sult, holoTC concentrations elevate as kidney function decreases
(32, 43). The same is true for total vitamin B-12, although to
a much lesser degree, because haptocorrin’s apparent molecular
mass exceeds that of albumin (44). Some studies have shown
only a marginal relation between kidney function and holoTC
and total vitamin B-12 concentrations (9, 45). The metabolic
markers show a marked concentration elevation with an increase
in serum creatinine (32, 45). As a result, with the use of the
metabolic markers, one might falsely categorize a person with
impaired kidney function to have a vitamin B-12 deﬁciency and
(less likely) to not have a deﬁciency with the use of holoTC.
Experts have expressed concern about a number of other
conditions, mainly in relation to holoTC and possibly total vi-
tamin B-12. Originally, we considered transcobalamin to be an
acute-phase protein elevated in conditions that involved acute
inﬂammation. However, more recent data indicate that trans-
cobalamin concentrations elevate only in conditions with mac-
rophage activation (31, 46). Other conditions that might elevate
holoTC concentrations include liver diseases (43, 47) and the
development of autoantibodies against transcobalamin (48, 49).
However, we need to do additional studies to examine the in-
ﬂuence of autoantibodies in relation to the new generation of
holoTC assays.
HoloTC REFERENCE INTERVALS
As we have discussed above, slight differences may occur in
the reference interval for holoTC because of transcobalamin
genotype, age, and sex (9, 22, 23, 26, 28). The reported variations
bythesefactors todatearerelativelysmall,and additionalstudies
need to address this issue before the need for adjusted reference
intervals by, for example, age, sex, and race is determined.
The reference intervals published so far are summarized in
Table 1. We have included only data on reasonably large groups
of healthy individuals. The current consensus seems to be that
a reference interval of 40–200 pmol/L is appropriate. Until re-
sults from additional studies are available, clinicians and re-
searchers should conﬁrm this interval locally before introduction
of holoTC into daily clinical practice or interpretation of the
results in population-based studies.
USEFULNESS OF holoTC MEASUREMENT
Nissen et al (51) have concluded that measurement of holoTC
and/or total transcobalamin is useful as a diagnostic tool in the
few patients with transcobalamin deﬁciency. This condition gives
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Vitamin B-12 status
Anumberofstudieshavepresenteddataontherelationbetween
holoTC and total vitamin B-12 concentrations across extreme to
insufﬁcient intakes ofthevitamin. Westudied healthy individuals
onadailyoralvitaminB-12doseof500lgandobservedamaximal
elevation in holoTC of ’50% by 3 d, with no further elevation by
the end of the study (84 d). The pattern for vitamin B-12 bound to
haptocorrinwasdifferent.Theinitialelevationwas’20%,butwe
observed a continuous increase throughout the study (35). MMA
showednochange,andthealterationintHcywasslowerthanthat
ofholoTC(52).Attheotherextreme,studiesinaveganpopulation
with an insufﬁcient vitamin B-12 intake suggest that holoTC de-
creasesbeforealterationsintheothervitaminB-12statusmarkers
(12). In between these extremes, holoTC, like the other vitamin
B-12 status markers, reﬂects the intake of vitamin B-12 (17).
Taken together, the above-mentioned studies suggest that hol-
oTC may prove most useful if the aim is to monitor a population
withaborderlinesuboptimalvitaminB-12supply.Incontrast,total
vitamin B-12 may be superior if the goal is to monitor a possible
surplus load of the vitamin. And ﬁnally, any of the markers for
vitamin B-12 deﬁciency may be used if the goal is to distinguish
between a normal vitamin B-12 status and an overt deﬁciency.
Vitamin B-12 uptake
TheobservationthatholoTCisamarkerofanacuteincreasein
the intake of vitamin B-12 led us to develop a routine test
(CobaSorb) for the study of vitamin B-12 uptake. To perform the
test, we removeblood samples before and after 1–2 d intake of an
oral dose of 3 times 9 lg vitamin B-12 daily and measure the el-
evation in holoTC. From an analytic point of view, we are able to
detect an elevation in holoTC of 10 pmol/L only if baseline
holoTC is reasonably low, and we initially recommended the test
to be used only if baseline holoTC was ,75 pmol/L (53). In an
early study on a cohort (n = 17) unable to absorb vitamin B-12
because of inherited lack of either intrinsic factor or its receptor,
we observed that none of the patients absorbed vitamin B-12 as
judgedbytheCobaSorbtest.Inotherwords,judgedbythesedata,
the sensitivity of CobaSorb is 1.00 (54). We calculated the spec-
iﬁcity to be 0.98 on the basis of results obtained on 57 healthy




vitamin B-12 is absorbed unchanged (ie, as cyanocobalamin). On
the basis of this observation, we developed a version of the Coba-
Sorb test in which we measure the increase in the amount of cya-
nocobalamin bound to transcobalamin. We named this version of
the test C-Cobasorb (55). Today we recommend the use of Coba-
Sorb to clarify whether a diagnosed vitamin B-12 deﬁciency is
causedbyaninabilitytoabsorbthevitamin,andrecommendthetest
be judged in the following manner. We judge the patient able to
absorb vitamin B-12 if holoTC increases .10 pmol/L and .22%
after 2 d intake of an oral dose of 3 times 9 lg vitamin B-12 daily.
We recommend C-CobaSorb be performed in patients with a base-
line holoTC .65 pmol/L and not judged to absorb vitamin B-12
based on the CobaSorb test (55). We stress that currently the
CobaSorb testshave beenusedonly togivea “yes” or“no”answer
related totheabsorptionofvitaminB-12.Wedo notknowwhether
TABLE 1
Selected reference intervals for holotranscobalamin (holoTC) with the use







Radioimmunoassay 400 24–160 105 22
37–170 303 28
Microbiology ,150 42–160 500 9
ELISA 100 40–150 137 23
Direct 200 19–130 292 26
36–220 276 50
1 ELISA, enzyme-linked immunosorbent assay.
2 Radioimmunoassay: precipitation of transcobalamin on antibody-
coated beads and measurement of vitamin B-12 with the use of an isotope
dilution method. Microbiology: precipitation of transcobalamin by antibody-
coated beads and measurement of trapped vitamin B-12 with the use of
a microbiological method. ELISA: measurement of holoTC with the use
of ELISA after removal of apotranscobalamin with vitamin B-12–coated
beads. Direct: measurement of holoTC by ELISA, with the use of an anti-
body that is speciﬁc for holoTC.
FIGURE 3. Holotranscobalamin (holoTC) and cobalamin (vitamin B-12)
in relation to methylmalonic acid (MMA). The ﬁgure shows combined data
from Hvas and Nexo (32) and Clarke et al (56). The ﬁgure includes 1842
data sets divided into tertiles in accordance with elevating MMAvalues. The
x axis denotes the mean MMA value in each group. The upper panel shows
the fractional change in holoTC (d) and haptocorrin-bound vitamin B-12
(total vitamin B-12 minus holoTC values; s). To calculate the fractional
change, we divided the mean for each group by the mean for the group with
the lowest MMA values. The lower panel shows the absolute values for
holoTC (d), haptocorrin-bound vitamin B-12 (s), and total vitamin B-12
(·). The ﬁgure depicts the mean (6SEM) for each group.
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Vitamin B-12 deﬁciency
We and others perceive holoTC as an early marker of vitamin
B-12 deﬁciency, but ﬁnal proof of this concept would require
a study in which a cohort of patients is followed as their vitamin
B-12 status shifts from normal to overt deﬁciency. Such a study is
not feasible because you would have an obligation to treat the
patient as soon as the ﬁrst sign of deﬁciency became apparent.
However,asshowninFigure3,weprovideindirect evidencethat
suggests that holoTC is a better marker than is vitamin B-12. We
analyzed the combined data from a study on community-dwelling
elderly adults (56) and from a study on patients referred to the
hospitalforevaluation ofsuspected vitaminB-12deﬁciency(32).
The ﬁgure shows that holoTC accounts for most of the change in
vitamin B-12 both expressed in relative (upper panel) or absolute
(lower panel) terms in the groups of patients with increasing vi-
tamin B-12deﬁciencyas judged from anincrease in MMAvalues
from 0.25 to .1 lmol. Interestingly, holoTC levels off, whereas




a change in total vitamin B-12 but not in holoTC.
Numerous studies have compared holoTC’s performance with
thatoftotalvitaminB-12foridentiﬁcationofpatientswithvitamin
B-12deﬁciency.MostofthesestudiesusedanelevatedMMAand
possibly tHcy concentration to identify individuals with and
without vitamin B-12 deﬁciency (Table 2). All the studies shown
in Table 2 involved patients with normal kidney function, and all
but one of these studies showed that holoTC’s performance is
better than that of vitamin B-12, independent of the cutoff MMA
value they used to classify patients’ vitamin B-12 status (32, 56–
59). The one study that showed that vitamin B-12 was superior to
holoTCincludedveryfewpatientsforassessmentofholoTC(59).
Thefewstudiesinpatientswithimpairedkidneyfunctionshowed
that holoTC is also superior in these patients (56, 58). Although
holoTC seems to identify patients with elevated MMA concen-
trations more effectively than does vitamin B-12, Miller et al (60)
have suggested that the use of both parameters in combination is
preferable.
Fedosov (61) recently used mathematic modeling to classify
patients’ vitamin B-12 status with the use of all 4 deﬁciency
markers (holoTC, total vitamin B-12, MMA, and tHcy). He then
determined how well each marker would have predicted vitamin
B-12 deﬁciency, and showed holoTC [area under the receiver
operating curve (AUC) = 0.93] to be similar to MMA (AUC =
0.92) and better than total vitamin B-12 (AUC = 0.88) and tHcy
(AUC = 0.87).
CONCLUSIONS
More than 20 y ago, insights into the physiology of vitamin
B-12 led tothesuggestion thatholoTC mightbea sensitivemarker
ofearlyvitaminB-12deﬁciency.Sincethen,holoTCmeasurement
has come of age. Today, we can conclude that holoTC seems more
suitable than total vitamin B-12 for diagnosis of vitamin B-12
deﬁciency. However, to date, holoTC has not acquired wide
clinical acceptance, most likely because of the test’s cost and
limited availability. On the basis of the data we present in this
review, we predict that holoTC will also be an excellent marker
for monitoring a population’s vitamin B-12 status. Currently,
a strong need exists for studies that can prove or disprove this
prediction.
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